Last updated: February 13, 2026
What is the Drug?
NDC 69315-0136 refers to a prescription drug, identified by the National Drug Code (NDC). This code corresponds to Xyrem (sodium oxybate), a central nervous system depressant primarily prescribed for narcolepsy with cataplexy and other sleep disorders. The drug plays a critical role in managing symptoms but faces regulatory and market constraints given its high abuse potential.
Market Size and Demand Drivers
Global Narcolepsy Treatment Market
- Estimated value in 2022: approximately $7 billion.
- Projected Compound Annual Growth Rate (CAGR): 6.5% from 2022 to 2027.
- Primary markets: North America (largest), Europe, and select Asia-Pacific countries.
Xyrem-Specific Market Insights
- In the U.S., the drug holds a dominant position for narcolepsy treatment, with over 70% of prescriptions among oxybate therapies.
- Estimated U.S. prescriptions in 2022: 180,000–220,000 units annually.
- Growth drivers include expanding diagnosis rates of narcolepsy and off-label use for other sleep disorders.
Competitive Landscape
| Product Name |
Class |
Market Share |
Price (per treatment gram) |
Regulatory Status |
| Xyrem (sodium oxybate) |
Central nervous system depressant |
80-90% |
$60–$80 |
FDA approved; Schedule III |
| Other oxybate formulations |
Similar |
10-20% |
$50–$70 |
Restricted distribution |
- Innovators: Jazz Pharmaceuticals markets the original formulation.
- Generics: No approved generics in the U.S. as of 2023, maintaining high barriers to entry.
Pricing Factors and Trends
- Pricing Stability: The official wholesale acquisition cost (WAC) for Xyrem remains relatively stable, with minor annual increases averaging 3–5%.
- Cost Drivers: FDA’s Risk Evaluation and Mitigation Strategies (REMS), strict distribution controls, and manufacturing complexity influence sustained high prices.
- Market Exclusivity: Patent protections and Orphan Drug exclusivity (until at least 2027) prevent generic competition.
Regulatory Environment Impact
- FDA REMS Program: Limits distribution to certified pharmacies and prescribers to mitigate abuse.
- Patent and Exclusivity: Patents issued in 2000 and extensions protect market share until at least 2027.
- Off-label Use Restrictions: Limited by regulation, preserving market segmentation.
Price Projections (2023–2028)
| Year |
Average Price per Treatment Gram |
Notes |
| 2023 |
$70 |
Base case, stable with prior years |
| 2024 |
$73 |
Slight increase due to inflation and regulatory costs |
| 2025 |
$76 |
Anticipated stabilization; no significant patent challenges |
| 2026 |
$78 |
Approaching patent expiry; price pressures expected |
| 2027 |
$79 |
Slight rise; market may face generic competition post-patent |
| 2028 |
$65–$70 |
Potential drop if generics enter, depending on regulatory approvals |
Note: The sharp decline might not occur immediately upon patent expiry due to regulatory complexities and manufacturing barriers.
Potential Impact of Biosimilars and Generics
- No biosimilar or generic options expected before patent expiry.
- Market entry barriers include REMS restrictions, manufacturing complexity, and regulatory hurdles.
Investment and R&D Considerations
- Developing competing therapies requires significant time (7–10 years) and costs (estimated $1.5–$3 billion).
- Sector trend favors developing safer, abuse-deterrent formulations or alternative therapies with fewer regulatory restrictions.
Key Takeaways
- The current therapeutic market for NDC 69315-0136 is high-priced due to market exclusivity, regulatory controls, and manufacturing complexity.
- Price stability is expected until patent expiration, projected around 2027.
- Market growth hinges on increased diagnosis of narcolepsy and potential off-label indications.
- Entry of generics is unlikely before 2027, maintaining pricing power.
- Post-expiry, significant price reductions are probable, influenced by regulatory pathways and manufacturing barriers.
FAQs
1. What are the main barriers to generic entry for NDC 69315-0136?
The main barriers include patent protections extending until at least 2027, strict REMS distribution restrictions, and complex manufacturing processes.
2. How might regulatory changes affect pricing?
Easing REMS restrictions or approving generics would likely lead to price decreases; however, regulatory timelines and resistance may delay this.
3. What alternative therapies are emerging in this space?
Research focuses on novel sleep disorder treatments with lower abuse potential, including orexin receptor antagonists and other neuroactive compounds.
4. How does patent expiry influence the future market?
Post-expiry, competition from generics could reduce prices by 50–70%, affecting revenue and R&D incentives for innovators.
5. Are there significant off-label uses influencing demand?
Yes, off-label applications for conditions like alcohol dependence or fibromyalgia, although limited, can affect overall demand patterns.
Sources:
- MarketWatch. "Global narcolepsy drugs market report." 2022.
- U.S. FDA. "Xyrem (sodium oxybate) REMS," 2023.
- Jazz Pharmaceuticals. Annual financial reports, 2022.
- EvaluatePharma. "Pharmaceutical market data," 2023.
- FDA. "Patent and exclusivity data," 2023.
